JPRN-UMIN000006907
Recruiting
未知
Anticoagulation therapy around catheter ablation for atrial fibrillation -Dabigatran vs. Warfarin- - DAWN-AF Trial
DAWN-AF-Trial Society0 sites100 target enrollmentDecember 19, 2011
ConditionsAtrial fibrillation
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Atrial fibrillation
- Sponsor
- DAWN-AF-Trial Society
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who do not satisfy inclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
the effect of plavix in post coronary artery bypass graft/coronary endarterectomy patientsCoronary artery disease.Atherosclerotic heart disease Coronary (artery): atheroma atherosclerosis disease sclerosisIRCT2016102730410N2Babol University of Medical Sciences, Deputy of Research & Technology55
Completed
Not Applicable
Catheter ablation for the cure of atrial fibrillation studyAtrial fibrillationCirculatory SystemISRCTN46898887Casa di Cura San Michele137
Completed
Not Applicable
Thrombolysis via catheter in treatment of Pulmonary EmboliPulmonary emboli.Pulmonary embolismIRCT20181022041406N1Rajaie Cardiovascular Medical and Research Center288
Recruiting
Phase 4
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial FibrillationNCT04432220Yonsei University840
Active, not recruiting
Phase 1
Protection offered by N-Acetylcysteine against radiation induced cellular damage in patients undergoing ablation procedures because of cardiac arrhythmia.Patients with Cardiac Arrhythmia who undergo catheter ablation procedures guided by x-Ray imagingMedDRA version: 23.1Level: LLTClassification code 10007518Term: Cardiac arrhythmiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2019-001995-12-ITCENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO550